Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
Featuring a variety of artificial intelligence (AI) tools to enhance breast cancer detection with digital breast tomosynthesis (DBT), the SmartMammo Dx software has garnered expanded clearance from the Food and Drug Administration (FDA).1
Previously cleared by the FDA in 2021 for use with Hologic mammography systems, SmartMammo Dx (DeepHealth/RadNet) can now be used with Senographe Pristina (GE HealthCare) mammography platforms.
Assigning finding- and case-specific suspicion levels for breast cancer based on identification of soft tissue lesions and calcifications on digital breast tomosynthesis (DBT), the SmartMammo Dx software recently garnered expanded FDA clearance for use with the Senographe Pristina (GE HealthCare) mammography platforms. (Image courtesy of DeepHealth.)
DeepHealth said the SmartMammo Dx software assigns finding- and case-specific suspicion levels based on identification of soft tissue lesions and calcifications on DBT exams. The SmartMammo software has facilitated 23 percent higher detection of breast cancer in women with dense breasts and a 20 percent higher detection of breast cancer detection in African American women, according to DeepHealth.2
“This FDA clearance allows us to expand access to high-quality breast cancer screening to more patients,” said Kees Wesdorp, the president and CEO of DeepHealth. “By bringing SmartMammo’s improved cancer detection to GE HealthCare’s mammography systems, more providers can harness the power of AI to help redefine radiology workflows and address key challenges across the imaging value chain, to improve speed, clinical accuracy, operational efficiency, and elevate patient care.”
References
1. RadNet. Correction: RadNet’s DeepHealth subsidiary expands FDA clearance for SmartMammo™ solution. GlobeNewswire. Available at: https://www.globenewswire.com/news-release/2024/11/29/2989189/0/en/CORRECTION-RadNet-s-DeepHealth-Subsidiary-Expands-FDA-Clearance-for-SmartMammo-Solution.html . Published November 29, 2024. Accessed November 29, 2024.
2. DeepHealth. SmartMammo. Available at: https://deephealth.com/population-health/smart-mammo/ . Accessed November 29, 2024.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
